Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo H Paredes

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Lancet (London, England)|March 10, 2018
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen A Harrison, Mary E Rinella, Manal F Abdelmalek, et al.
Journal of Hepatology|March 22, 2021
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohortStephen A Harrison, Samer Gawrieh, Katharine Roberts, et al.
Gastroenterology|August 12, 2020
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic SteatohepatitisStephen A Harrison, Guy Neff, Cynthia D Guy, et al.
Hepatology (Baltimore, Md.)|March 27, 2024
Quality measures in pre-liver transplant care by the Practice Metrics Committee of the American Association for the Study of Liver DiseasesMayur Brahmania, Alexander Kuo, Elliot B Tapper, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Lancet (London, England)|March 10, 2018
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialStephen A Harrison, Mary E Rinella, Manal F Abdelmalek, et al.
Journal of Hepatology|March 22, 2021
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohortStephen A Harrison, Samer Gawrieh, Katharine Roberts, et al.
Gastroenterology|August 12, 2020
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic SteatohepatitisStephen A Harrison, Guy Neff, Cynthia D Guy, et al.
Hepatology (Baltimore, Md.)|March 27, 2024
Quality measures in pre-liver transplant care by the Practice Metrics Committee of the American Association for the Study of Liver DiseasesMayur Brahmania, Alexander Kuo, Elliot B Tapper, et al.
Pageof 2